Searched for
CDMO BUSINESS
Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growthLaurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by r...- Index returns likely to be slightly above long-term averages over next 2 years: Mirae Asset CIO Neelesh Surana on market outlook, fund strategiesMirae Asset Investment Managers (India)’s equity funds have experienced a period of underperformance—the first major blip since inception i...
- Shantha Biologics to make injectable drug cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- MF Tracker: TRUSTMF Small Cap Fund topped one-year return chart with 22.77% gains. Can the rally continue?TRUSTMF Small Cap Fund emerged as the best-performing equity mutual fund over the past year, delivering a 22.78% return and outperforming b...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- The hidden reason global capital is looking beyond India for future growthForeign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI a...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Banking, capital goods and midcaps seen driving market's next rally: Ashish ChaturmohtaIndian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- ETMarkets PMS Talk | A 'private equity approach' to public markets has driven our investing success for 15 years: Sameer ShahValueQuest's Sameer Shah champions a private equity approach to public markets. He focuses on deep research and conviction in identifying t...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- True North buys 25% stake in pharma co EmbioPrivate equity firm True North is investing approximately $50 million in Embio Ltd. Embio manufactures Active Pharmaceutical Ingredients fo...
- Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOsDeepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received S...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
Load More
